open access

Vol 3, No 2 (2007)
Review paper
Published online: 2007-03-14
Get Citation

Evolving strategies in primary therapy for chronic lymphocytic leukemia

Krzysztof Warzocha
Onkol. Prak. Klin 2007;3(2):78-86.

open access

Vol 3, No 2 (2007)
REVIEW ARTICLES
Published online: 2007-03-14

Abstract

Chronic lymphocytic leukemia (CLL) has the highest prevalence of any adult leukemia. The last few years have defined some important prognostic factors, which should be taken into consideration upon treatment planning. In the majority of patients, therapy should be aimed to obtain complete remission and to prolong its duration and overall survival. The best results are presently reported with combined chemotherapy, based on purine analogs and cyclophosphamide. Further improvement of the therapy results with rituximab and/or alemtuzumab, as presented in the phase II studies and comparative analyses with historical patients treated with chemotherapy alone, warrants confirmation by prospective trials. Although molecular remission has been reported in many patients treated with chemioimmunotherapy, available data indicate that its use, even with the support of autologous hematopoietic stem cell transplantation is not curative. Allogeneic transplantation is the only potentially curative therapy for CLL, however, the major treatment-related toxicity have restricted the use of myeloablative strategy in this setting. New management options such as non-myeloablative allogeneic transplants have emerged, which will hopefully improve transplant tolerability as well as its applicability to a wider population of patients. This article reviews the results of clinical trials, which have allowed defining new therapeutic strategies of CLL in recent years.

Abstract

Chronic lymphocytic leukemia (CLL) has the highest prevalence of any adult leukemia. The last few years have defined some important prognostic factors, which should be taken into consideration upon treatment planning. In the majority of patients, therapy should be aimed to obtain complete remission and to prolong its duration and overall survival. The best results are presently reported with combined chemotherapy, based on purine analogs and cyclophosphamide. Further improvement of the therapy results with rituximab and/or alemtuzumab, as presented in the phase II studies and comparative analyses with historical patients treated with chemotherapy alone, warrants confirmation by prospective trials. Although molecular remission has been reported in many patients treated with chemioimmunotherapy, available data indicate that its use, even with the support of autologous hematopoietic stem cell transplantation is not curative. Allogeneic transplantation is the only potentially curative therapy for CLL, however, the major treatment-related toxicity have restricted the use of myeloablative strategy in this setting. New management options such as non-myeloablative allogeneic transplants have emerged, which will hopefully improve transplant tolerability as well as its applicability to a wider population of patients. This article reviews the results of clinical trials, which have allowed defining new therapeutic strategies of CLL in recent years.
Get Citation

Keywords

lymphocytic leukemia; prognostic factors; treatment; chemotherapy; immunotherapy; hematopoietic stem cell transplantation

About this article
Title

Evolving strategies in primary therapy for chronic lymphocytic leukemia

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 2 (2007)

Article type

Review paper

Pages

78-86

Published online

2007-03-14

Bibliographic record

Onkol. Prak. Klin 2007;3(2):78-86.

Keywords

lymphocytic leukemia
prognostic factors
treatment
chemotherapy
immunotherapy
hematopoietic stem cell transplantation

Authors

Krzysztof Warzocha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl